Prostate cancer is the cancer that occurs in the male's prostate.
It is the most common cancer in men >50 years of age.
Signs and symptoms include weak urinary stream, polyuria, nocturia, hematuria, erectile dysfunction, pelvic pain, back pain, chest pain, lower extremity weakness or numbness and loss of bowel or bladder control.
Preoperative biopsy Gleason grade (4 + 4 vs any Gleason pattern 5) subclassification of high-risk prostate cancer identifies men at highest risk for progression, according to a study. Furthermore, any Gleason 5 on biopsy correlates with a higher risk of metastasis, as well as prostate cancer-specific and overall mortality.
The use of oral androgen receptor inhibitor enzalutamide may benefit chemotherapy-naïve patients with metastatic castration-resistant prostate cancer and low baseline prostate specific antigen irrespective of disease burden, signifying that targeting the androgen receptor signalling pathway is a therapeutic option in similar patients, suggests a recent study.
Indication and demand for genetic testing have increased in recent years, with tests becoming more readily available and affordable, says a leading oncologist at ESMO Asia 2017, highlighting that appreciation of ethical, social, and legal implications of testing and proper test interpretation are important for optimal patient management.
Enzalutamide demonstrates antitumour activity for up to 3 years in patients with hormone-naïve prostate cancer, according to a follow-up analysis of a phase II trial. Specifically, results for bone mineral density, global health status and safety at year 3 are similar to those at year 2.
Pomegranate juice and extract are safe but do not favourably influence outcomes in prostate cancer patients with biochemical recurrence, a study has shown. However, a subset of BCR patients with the manganese superoxide dismutase AA genotype appear to respond positively to the antioxidant effects of pomegranate.
Active surveillance on patients with localized prostate cancer results in a decreased rate of active surveillance failure, prostate cancer specific mortality and metastases regardless of baseline risk, according to a recent study.
Both denosumab and bisphosphonates enhance bone mineral density (BMD) in men with nonmetastatic prostate cancer who are receiving androgen deprivation therapy (ADT), according to a systematic review and meta-analysis. In addition, denosumab lowers the risk for radiographic vertebral fractures.
Prostate biopsy using the multiparametric MRI/ultrasound fusion-guided (mpMRI/US) technique improves prostate cancer diagnosis and reduces the detection of clinically insignificant cancers, according to data presented the 15th Urological Association of Asia Congress (UAA 2017) held recently in Hong Kong.
Practice-changing results from several clinical trials reported in the past 2 years have offered new effective treatment options for hormone-naïve prostate cancer (PC) patients, according to Dr Gerhardt Attard from the Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, UK, who spoke at the 15th Urological Association of Asia Congress (UAA 2017) held recently in Hong Kong.
The current protocol for risk stratification of prostate cancer at diagnosis is inaccurate, according to new data from the ProtecT (Prostate Testing for Cancer and Treatment) trial presented at the 15th Urological Association of Asia Congress (UAA 2017) held recently in Hong Kong.
In addition to the known evils of maternal smoking during pregnancy on the son’s semen quality, prenatal exposure to paternal smoking can also be harmful, according to data from the large Danish National Birth Cohort (DNBC) presented at the ESHRE 2019 Meeting.
Men with metastatic hormone-sensitive prostate cancer (mHSPC) who receive testosterone suppression therapy may have a better survival outcome with the addition of enzalutamide over other non-steroidal anti-androgen (NSAA) therapies, according to the phase III ENZAMET* trial.